Postoperative chemotherapy for non–small cell lung cancer: A systematic review and meta-analysis Artyom Sedrakyan, MD, PhD, Jan van Der Meulen, PhD,

Slides:

Advertisements

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Advertisements

Manuel J. Antunes, MD, PhD, DSc

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Lung cancer screening: No more excuses

“Lead from the front”: Participative leadership

Yesterday's heroic measure is now standard procedure: Extracorporeal membrane oxygenation as a bridge to lung transplant Victor van Berkel, MD, PhD

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer

Intrinsic cardiac stem cells are essential for regeneration

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Victor van Berkel, MD, PhD

William M. DeCampli, MD, PhD

Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials

Scott A. Hittinger, MD, Tom P. Theruvath, MD, PhD, John S

What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice Tom.

Effect of statins on atrial fibrillation after cardiac surgery: A duration- and dose-response meta-analysis Wendy T. Chen, PharmD, Guru M. Krishnan,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The lord of the rings Antonio Miceli, MD, PhD

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

It's not “just a shunt” but sometimes it should be…

Military surgeons just want to have fun

A first start for lung transplantation?

Confusion still exists regarding postoperative delirium and its etiology after esophagectomy Robert B. Cameron, MD The Journal of Thoracic and Cardiovascular.

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

A fate worse than death Jennifer S. Lawton, MD

Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: Duminda N Wijeysundera, MD, Jennifer S Naik, MD, W Scott Beattie, MD,

Internal validation of risk models in lung resection surgery: Bootstrap versus training- and-test sampling Alessandro Brunelli, MD, Gaetano Rocco, MD

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Functional tricuspid pathology: To treat or not to treat

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

First nights, the adrenal axis, and steroids

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

The continuing challenge of congenital heart disease in China

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

“The more things change…”: The challenges ahead

Aritoshi Hattori, MD, Kenji Suzuki, MD

The Journal of Thoracic and Cardiovascular Surgery

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Who should decide margin length in pulmonary excision of lung cancer?

Did you like Terminator 3 better than Terminator 2

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

A good chimney requires a good sweep

Descending thoracic and thoracoabdominal aortic aneurysms: “Busted”

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Postoperative chemotherapy for non–small cell lung cancer: A systematic review and meta-analysis Artyom Sedrakyan, MD, PhD, Jan van Der Meulen, PhD, Ken O'Byrne, MD, Joseph Prendiville, PhD, FRCP, Jennifer Hill, PhD, Tom Treasure, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery Volume 128, Issue 3, Pages 414-419 (September 2004) DOI: 10.1016/j.jtcvs.2004.04.027

Figure 1 Meta-analysis of postoperative chemotherapy trials for NSCLC. The first 8 studies in the cisplatin subcategory and the first 4 studies in the UFT subcategory were originally combined by NSCLCCG. The horizontal axis is based on a log scale for HR (corresponds to relative risk) ranging from 0.5 to 2.0. The black boxes and lines correspond to HR estimates and 95% CIs for individual studies. Arrows show that the 95% CI extends beyond 0.5 or 2.0. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 414-419DOI: (10.1016/j.jtcvs.2004.04.027)

Figure 2 Cumulative meta-analysis of postoperative chemotherapy trials for NSCLC. Studies are ordered according to the date of the first report. The first 8 studies in the cisplatin subcategory and the first 4 studies in the UFT subcategory were originally combined by NSCLCCG. The horizontal axis is based on a log scale for HR (corresponds to relative risk) ranging from 0.5 to 2.0. The black boxes and lines correspond to HR estimates and 95% CIs for individual studies. Arrows show that the 95% CI extends beyond 0.5 or 2.0. The estimate of each individual trial is added to the estimate observed in all previous studies to perform cumulative meta-analyses. If the direction of the association is the same, then no difference in the overall estimate is observed, but 95% CIs shrink because of increased sample size. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 414-419DOI: (10.1016/j.jtcvs.2004.04.027)

Figure 3 Subgroup analyses of cisplatin-based postoperative chemotherapy trials by Japanese and European/North American participants. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 414-419DOI: (10.1016/j.jtcvs.2004.04.027)